

## CORRECTION

View Article Online  
View Journal | View Issue



Cite this: *J. Mater. Chem. B*, 2024, 12, 275

## Correction: Mitochondria-targeting nanozyme alleviating temporomandibular joint pain by inhibiting the TNF $\alpha$ /NF- $\kappa$ B/NEAT1 pathway

Qian Bai,<sup>a</sup> Yaoyao Zhou,<sup>a</sup> Xiaona Cui,<sup>ab</sup> Haichao Si,<sup>e</sup> Tingting Wu,<sup>a</sup> Abdul Nasir,<sup>ac</sup> Heng Ma,<sup>ac</sup> Junyue Xing,<sup>d</sup> Yingying Wang,<sup>d</sup> Xiaolei Cheng,<sup>d</sup> Xiaojun Liu,<sup>\*b</sup> Shaoyan Qi,<sup>\*b</sup> Zhisong Li<sup>c</sup> and Hao Tang<sup>\*d</sup>

DOI: 10.1039/d3tb90183a

rsc.li/materials-b

Correction for 'Mitochondria-targeting nanozyme alleviating temporomandibular joint pain by inhibiting the TNF $\alpha$ /NF- $\kappa$ B/NEAT1 pathway' by Qian Bai et al., *J. Mater. Chem. B*, 2023, <https://doi.org/10.1039/d3tb00929g>.

The authors regret the error in Fig. 6 due to a figure compilation error. The corrected Fig. 6 is shown below.

<sup>a</sup> Medical Research Center, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China


<sup>b</sup> Department of Critical Care Medicine, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. E-mail: liuxiaojunzzu@163.com, qishaoyan1970@163.com

<sup>c</sup> Department of Anesthesiology and Perioperative Medicine, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

<sup>d</sup> National Health Commission Key Laboratory of Cardiovascular Regenerative Medicine, Heart Center of Henan Provincial People's Hospital, Central China Fuwai Hospital of Zhengzhou University, Fuwai Central China Cardiovascular Hospital & Central China Branch of National Center for Cardiovascular Diseases, Zhengzhou, Henan, 451464, China. E-mail: tangpku\_zzuhao@zzu.edu.cn

<sup>e</sup> Department of Anesthesiology, Nanyang Central Hospital, Nanyang, Henan, China





**Fig. 6** Intravenous Mito-Ru MOF injection 30 min after intra-TMJ CFA injection downregulated the TNF $\alpha$ /NF- $\kappa$ B/Neat1 pathways in a mouse TMD pain model. (A) Single i.v. Mito-Ru MOF injection 30 min after intra-TMJ CFA injection downregulated Neat1 in Sp5C in mouse TMD pain model after 3 d;  $^{**}P < 0.01$ ;  $^{****}P < 0.0001$ , two-way ANOVA,  $N = 18$ . (B) Single i.v. Mito-Ru MOF injection 30 min after TMJ CFA injection downregulated p-p65 in Sp5C in mouse TMD pain model after 3 d;  $^{****}P < 0.0001$  vs. CFA + vehicle; two-way ANOVA,  $N = 39$ . (C) Single i.v. Mito-Ru MOF injection 30 min after TMJ CFA/saline injection did not alter p65 expression in Sp5C after 3 d;  $^{ns}P > 0.05$ ,  $N = 27$ . (D) Single i.v. Mito-Ru MOF injection 30 min after TMJ CFA injection counteracted the increase in p-p65 immunofluorescence intensity in Sp5C in mouse TMD pain model after 3 d (scale bar = 400  $\mu$ m). (E) Statistical analysis of data in (D)  $^{****}P < 0.0001$  vs. CFA + vehicle group,  $N = 3$ , two-way ANOVA. (F) Intra-Sp5C NF- $\kappa$ B injection in downregulated Neat1 in naive mice;  $^{**}P < 0.01$  vs. Scramble control,  $N = 5$ ;  $t$ -test. (G) Single i.v. Mito-Ru MOF injection 30 min after intra-TMJ CFA injection downregulated TNF- $\alpha$  in Sp5C in mouse TMD pain model after 3 d;  $^{***}P < 0.001$  vs. CFA + vehicle,  $N = 4$ ; two-way ANOVA.

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

